PHOENIX

Meridian in Michigan and the Centene Foundation Announce $1.1 Million Grant to Wayne Mobile Health Unit

Retrieved on: 
Thursday, February 15, 2024

DETROIT, Feb. 15, 2024 /PRNewswire/ -- Meridian in Michigan, a leading managed care organization in the state of Michigan and a wholly owned subsidiary of Centene Corporation (NYSE: CNC), announced a partnership with the Wayne Mobile Health Unit (WMHU) to improve maternal and infant health and broadly support the WMHU's community outreach efforts to deliver preventative health services directly in neighborhoods, at homes and in workplaces.

Key Points: 
  • The hope is the initiative will reduce maternal health mortality rates, which are disproportionately higher among Black and Hispanic women.
  • "Meridian is pleased to collaborate with the Wayne Mobile Health Unit and our other partners to provide targeted services in an efficient way to urban and rural communities across Michigan," said Dr. Kay Judge, Meridian's Chief Medical Officer.
  • Among pregnancy-related maternal deaths between 2015 and 2019, Michigan Department of Health and Human Services found more than 63% were preventable.
  • "The Wayne Mobile Health Unit is incredibly grateful to the Centene Foundation for their substantial financial commitment," said Dr. Phillip Levy, Associate Vice President for Translational Science at Wayne State University and Director of the Wayne Mobile Health Unit.

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Tuesday, November 14, 2023

ET

Key Points: 
  • ET
    SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the three-months ended September 30, 2023, and provided a general business update.
  • “We made meaningful progress in the quarter advancing our clinical trials for Tinlarebant and are excited by our results,” said Dr. Tom Lin, Chairman and CEO of Belite Bio.
  • Third Quarter 2023 Financial Results:
    Cash: As of September 30, 2023, the Company had $54.5 million in cash.
  • Belite Bio will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update.

Xcimer Energy Announces Participation in Three Fusion Energy Hubs Awarded Funding by the U.S. Department of Energy

Retrieved on: 
Thursday, December 7, 2023

Xcimer Energy announced that it is participating in three fusion energy “hubs” that were awarded funding by the U.S. Department of Energy (DOE) today, through DOE’s Inertial Fusion Energy Science and Technology Accelerator Research program (IFE-STAR).

Key Points: 
  • Xcimer Energy announced that it is participating in three fusion energy “hubs” that were awarded funding by the U.S. Department of Energy (DOE) today, through DOE’s Inertial Fusion Energy Science and Technology Accelerator Research program (IFE-STAR).
  • Supported by the DOE Office of Fusion Energy Sciences (FES), the goal of the IFE-STAR program is to bring universities, national labs, and private companies together to advance inertial fusion energy and tackle the key remaining challenges in bringing IFE to the grid.
  • Xcimer will be working with STARFIRE on IFE chamber and balance of plant design, IFE-COLoR on elements of direct-drive fusion target development, and with RISE on key elements of laser driver technology.
  • PHOENIX will be utilized by both Xcimer and the RISE Hub to develop technologies that will enable transformative new results in inertial fusion energy.

RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND

Retrieved on: 
Monday, November 27, 2023

New data using a model for assessing mortality-adjusted progression (MAP) for clinical trials of ALS and encore posters will be presented.

Key Points: 
  • New data using a model for assessing mortality-adjusted progression (MAP) for clinical trials of ALS and encore posters will be presented.
  • Results from a post hoc analysis of the Phase 2 CENTAUR trial using this model are presented, which resulted in a nearly identical statistical outcome with increased precision as the primary analysis.
  • This poster provides an update on the progress made in developing a biomarker test that could make the diagnosis of ALS easier.
  • A copy of the abstract discussing the MAP model is published online in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration .

Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS

Retrieved on: 
Monday, December 4, 2023

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis (ALS) from the Phase 2 CENTAUR trial.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of analyses performed on neuroinflammatory biomarkers using plasma samples from participants with amyotrophic lateral sclerosis (ALS) from the Phase 2 CENTAUR trial.
  • During the CENTAUR trial, plasma samples were prospectively collected from trial participants for future biomarker analyses.
  • “Neuroinflammatory biomarkers are important for assessing disease progression and therapeutic response in ALS with chitinases and CRP emerging as potential treatment response biomarkers.
  • Further analyses of neuroinflammatory biomarkers are planned in the ongoing Phase 3 PHOENIX trial to confirm these results.

New Poll: Arizonans Support Clean Air and Climate Action More than Ever

Retrieved on: 
Thursday, December 14, 2023

PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Today, the American Lung Association in Arizona released updated polling that shows Arizona voters continue to support strong actions on clean air and climate change. Arizonans also overwhelmingly want to see policies to boost clean energy and solidly support efforts to encourage the transition to pollution-free vehicles.

Key Points: 
  • PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Today, the American Lung Association in Arizona released updated polling that shows Arizona voters continue to support strong actions on clean air and climate change.
  • Arizonans also overwhelmingly want to see policies to boost clean energy and solidly support efforts to encourage the transition to pollution-free vehicles.
  • "Arizona has some of the worst air pollution in the U.S., which creates a myriad of respiratory and cardiovascular concerns.
  • Global Strategy group has been conducting annual polls on clean air, clean energy, and climate issues in Arizona for the last four years.

Boom Supersonic selects Honeywell Anthem integrated flight deck for Overture aircraft

Retrieved on: 
Thursday, December 14, 2023

DENVER and PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Boom Supersonic, the company building the world's fastest airliner, has selected the Honeywell Anthem integrated flight deck for its Overture aircraft. As part of the agreement between the two companies, Honeywell's next-generation flight deck and its modular avionics platform will be incorporated into Overture.

Key Points: 
  • DENVER and PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Boom Supersonic , the company building the world's fastest airliner, has selected the Honeywell Anthem integrated flight deck for its Overture aircraft.
  • The Honeywell Anthem flight deck will be tailored for Overture's specific mission requirements, helping to enable exceptional situational awareness and enhanced safety.
  • Honeywell successfully completed the first flight of its Anthem integrated flight deck using its Pilatus PC-12 test aircraft in May 2023, paving the way for Federal Aviation Administration certification.
  • "Honeywell has an extensive history of aerospace innovation and shares our vision of a faster future through sustainable supersonic flight," said Blake Scholl, founder and CEO of Boom Supersonic.

Boom Supersonic selects Honeywell Anthem integrated flight deck for Overture aircraft

Retrieved on: 
Thursday, December 14, 2023

DENVER and PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Boom Supersonic, the company building the world's fastest airliner, has selected the Honeywell Anthem integrated flight deck for its Overture aircraft. As part of the agreement between the two companies, Honeywell's next-generation flight deck and its modular avionics platform will be incorporated into Overture.

Key Points: 
  • DENVER and PHOENIX, Dec. 14, 2023 /PRNewswire/ -- Boom Supersonic , the company building the world's fastest airliner, has selected the Honeywell Anthem integrated flight deck for its Overture aircraft.
  • The Honeywell Anthem flight deck will be tailored for Overture's specific mission requirements, helping to enable exceptional situational awareness and enhanced safety.
  • Honeywell successfully completed the first flight of its Anthem integrated flight deck using its Pilatus PC-12 test aircraft in May 2023, paving the way for Federal Aviation Administration certification.
  • "Honeywell has an extensive history of aerospace innovation and shares our vision of a faster future through sustainable supersonic flight," said Blake Scholl, founder and CEO of Boom Supersonic.

SenesTech Receives Substantial Orders for EVOLVE Soft Bait

Retrieved on: 
Thursday, December 14, 2023

PHOENIX, Dec. 14, 2023 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announces the expansion of Evolve™ Soft Bait ("Evolve") with substantial initial orders. Initially launched in November 2023, Evolve is the first and only soft bait product featuring technology that targets rodent populations by using non-lethal methods to restrict fertility.

Key Points: 
  • PHOENIX, Dec. 14, 2023 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES; "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations, today announces the expansion of Evolve™ Soft Bait ("Evolve") with substantial initial orders.
  • Initially launched in November 2023, Evolve is the first and only soft bait product featuring technology that targets rodent populations by using non-lethal methods to restrict fertility.
  • Within days of launch, we received pallet-sized orders for Evolve from a number of distributors.
  • "Many of the initial orders are from customers with prior, successful experience with ContraPest®, our first fertility control product, but who wanted a soft bait product.

Modigent Acquires Tebarco Mechanical, Expanding Footprint in Key Regional Market

Retrieved on: 
Thursday, December 14, 2023

PHOENIX and ATLANTA, Dec. 14, 2023 /PRNewswire/ -- Modigent, a market leader in infrastructure, technology and energy solutions, announced today the strategic acquisition of Tebarco Mechanical, based in Atlanta, Georgia.

Key Points: 
  • PHOENIX and ATLANTA, Dec. 14, 2023 /PRNewswire/ -- Modigent, a market leader in infrastructure, technology and energy solutions, announced today the strategic acquisition of Tebarco Mechanical, based in Atlanta, Georgia.
  • Daniel Bueschel, CEO of Modigent, commented on the acquisition: "Bringing Tebarco Mechanical into the Modigent family feels like a natural step of our growth.
  • This acquisition represents a new era for Modigent and Tebarco, combining traditional industry strengths with advanced technological capabilities that benefit clients across the United States.
  • It is also a pivotal step for Modigent as it continues to grow the company's geographic footprint.